The journal Cancer, which is a journal of the American Cancer Society – published results of the PROCEED registry, that found that men with advanced prostate cancer with low PSA had a median survival of nearly 4 years after treatment with PROVENGE® (sipuleucel-T). A median survival means that one half of the men who participated in the registry lived longer than four years.

The PROCEED registry is the largest real-world study of immunotherapy. Nearly 2,000 men with metastatic castrate-resistant prostate cancer (mCRPC) who received PROVENGE in everyday treatment settings – urology and medical oncology clinics across the U.S. – were enrolled in PROCEED between January 2011 and January 2014.

· Findings showed that men with mCRPC who were treated when their PSA was <5.27 ng/mL had a median survival of 47.7 months.

· In addition, 44% of these men did not receive any additional cancer treatments for at least one year – nearly all of these men were treated with PROVENGE as first-line therapy as recommended by the National Comprehensive Cancer Network (NCCN).

Link to Journal Article: https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.32445

Link to Press Release: https://www.businesswire.com/news/home/20190904005811/en/Largest-Real-World-Study-Immunotherapy-Shows-Men-Advanced

Here are some additional articles:

·OncLive - Real-World Data With Sipuleucel-T Showcase Promising OS in mCRPC

·The Pharma Letter - Certain advanced prostate cancer patients given Dendreon’s Provenge have four-year median survival

·Targeted Oncology - Real-World Study Shows Long-Term Survival of Sipuleucel-T in Prostate Cancer

·UroToday (press release) - Largest Real-World Study of Immunotherapy Shows Men with Advanced Prostate Cancer with Low PSA had a Median Survival of Nearly Four Years after Treatment with PROVENGE® (sipuleucel-T)

·UroToday (abstract) - Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer